A Phase 2 interventional study of PRA-216 and Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Prana Therapies Inc. Recruiting at 5 sites in Australia. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Prana Therapies Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies in Pulmonary Disease, Chronic Obstructive with a site in Australia — 15 open to participants now, 19 under way, 7 of them phase 3. Pulmonary Disease, Chronic Obstructive · Australia.
Among the 140 studies in Pulmonary Disease, Chronic Obstructive with a site in Australia, this one is the 114th largest by planned enrollment of the 132 interventional ones that give a count, is one of 4 that started in 2026, is one of 27 in phase 2, reaches primary completion later than 8 of the 18 other live ones, and was the 140th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →15 of the 140 studies in Pulmonary Disease, Chronic Obstructive with a site in Australia are open now. Recruiting first, the newest first:
Kither Biotech Srl · Sites in Australia
Ages 40–80
Atisama Therapeutics · Sites in Australia
Ages 18–80 · Healthy volunteers
Pfizer · Sites in Australia, United States, Argentina and 15 more countries
Ages 35–80
GlaxoSmithKline · Sites in Australia, United States, Bulgaria and 10 more countries
Ages 40–75
Sanofi · Sites in Australia, United States, Argentina and 23 more countries
Ages 40–80
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 36 · Phase 3 60 · Phase 4 10
First in 2000; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 441 across the 132 interventional studies, 108 across the 8 observational. Of the 115 that completed or were terminated, 65 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 140 have an industry lead sponsor. The 10 most frequent:
Prana Therapies Inc is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Prana Therapies Inc has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
8 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT06986070SMSbiotechInvestigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD). | 2026-12 |
| NCT06944925Bambusa TherapeuticsA Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) | 2027-01-31 |
| NCT07668518Kither Biotech SrlA Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD | 2027-03-31 |
| NCT07730281Prana Therapies IncPRA-216 COPD Safety and Biomarker Study | 2027-06-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 140 studies in Pulmonary Disease, Chronic Obstructive with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of PRA-216, administered by SC injection in participants with moderate to severe COPD who are on standard of care treatment consisting of dual (ICS/LAMA or ICS/LABA) or triple inhaled maintenance therapy (ICS, LABA and LAMA).
The study will enroll approximately 40 participants at multiple study site and participants will be randomized 1:1 to receive either PRA-216 or placebo subcutaneous injections four times throughout the study period.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with moderate to severe COPD will be randomized to receive PRA-216
Drug: PRA-216
Participants with moderate to severe COPD will be randomized to receive placebo
Drug: Placebo
biologic
matching placebo for PRA-216
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of PRA-216 in patients with moderate to severe COPD
Time frame: 40 weeks
The effect of multiple doses of PRA-216 compared to placebo on exhaled nitric oxide (FeNO) in COPD participants
FeNO is a non-invasive biomarker of airway inflammation in COPD. A higher number indicates higher inflammation. A reduction in FeNO levels might indicate functional activity of PRA-216.
Time frame: 40 weeks
Pharmacokinetics of PRA-216: Tmax in patients with COPD
Time of maximum observed concentration of PRA-216 in plasma
Time frame: 40 weeks
Pharmacokinetics of PRA-216: AUC in patients with COPD
Area under the curve of PRA-216 in plasma
Time frame: 40 weeks
Pharmacokinetics of PRA-216: Cmax in patients with COPD
Maximum concentration of PRA-216 in plasma.
Time frame: 40 weeks
Immunogenicity of PRA-216: ADA in patients with COPD
Incidence of anti-drug antibody following PRA-216 administration
Time frame: 40 weeks
Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 9 months is below that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Prana Therapies Inc